Nisa Investment Advisors’s Exagen XGN Stock Holding History

Nisa Investment Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-800	Closed	-$6K	–	2520
2022 Q1	$6K	Buy	+800	New	+$6.9K	﹤0.01%	2298

Other funds holding XGN

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Nisa Investment Advisors's XGN Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Exagen (XGN) in Q2 2022, closing a stake of 800 shares — an estimated $6K sold.

Nisa Investment Advisors first reported a position in XGN in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 47 funds tracked by Wall St. Rank hold XGN as of Q2 2022.

Nisa Investment Advisors reported no remaining Exagen position as of Q2 2022 after selling out during the quarter.
Nisa Investment Advisors sold 800 Exagen shares in Q2 2022, an estimated $6K.
Nisa Investment Advisors first reported a position in Exagen in Q1 2022 and held it in 1 quarter.
Nisa Investment Advisors's Exagen position peaked at $6K in Q1 2022.
47 funds tracked by Wall St. Rank held Exagen as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.